Compare W W Grainger Inc (GWW) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
W W Grainger Inc vs Twist Bioscience Corp — how do they compare? W W Grainger Inc trades at $1,400.22 (market cap $64.75B), while Twist Bioscience Corp trades at $92.63 (market cap $5.76B). The key difference: W W Grainger Inc is far larger — about 11.2× Twist Bioscience Corp's market cap, and W W Grainger Inc pays a 0.68% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| GWW | TWST | |
|---|---|---|
Market Cap | $64.75B | $5.76B |
Sector | Technology | Health |
52-Week High | $1.39K | $102.88 |
52-Week Low | $918.18 | $24.16 |
Enterprise Value | $66.84B | $5.69B |
Dividend Yield | 0.68% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GWW trades at $1,391.07, up 1.46% with strong technical momentum and bullish moving averages. The company reported solid Q1 2026 earnings of $11.65 per share, beating estimates, and raised full-year guidance. With revenue growth to $18.4B and net profit margin improving to 9.69%, fundamentals remain robust despite elevated valuation multiples.
Outlook remains positive with analyst consensus price target of $1,260 offering modest upside. Key risks include high P/E ratio of 36.88 and competitive pressures in industrial distribution. The stock presents a quality growth opportunity but requires monitoring of valuation sustainability amid economic uncertainties.
Twist Bioscience (TWST) trades at $90.33, down 2.46% on the day, with a bullish technical outlook despite recent earnings misses. The company shows strong revenue growth from $204M in 2022 to $377M in 2025, though it remains unprofitable with a -19.85% net margin. Analyst sentiment is positive with 11 buy ratings and a $91.63 consensus target, while recent news highlights AI collaborations and upcoming Q3 earnings.
TWST presents a growth story with improving margins and AI-driven demand, but profitability concerns and consistent cash burn pose risks. The stock trades near analyst targets, suggesting limited near-term upside without earnings acceleration. Key catalysts include Q3 results on August 3, 2026, and execution on path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About W W Grainger Inc
Grainger is a leading broad-line distributor of maintenance, repair, and operating (MRO) products. It serves millions of customers worldwide through an integrated network of branches and digital platforms.
Read more on GWW →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
